Researchers identify a new way to promote tissue regeneration

Houston Methodist researchers have identified an immune pathway that promotes the formation of a cell that can develop into new tissues and organs. In a new study published in the journal Stem Cells, a team led by John P. Cooke, M.D., Ph.D., chair of Cardiovascular Sciences, Houston Methodist Research Institute, described how activation of innate immunity enhances nuclear reprogramming, one of the first steps in tissue regeneration, or the formation of new tissues and organs from a single cell in the body.

"We found that activating the innate immune system opens up the DNA," said Cooke, the study's senior author. "This open state enhances the formation of induced pluripotent stem cells (iPSCs) or cells that can have the ability to regenerate into other cell types and tissues, such as that of the brain, heart or liver."

The use of iPSCs to generate tissues would revolutionize transplantation, facilitating the growth of artificial organs. Cellular nuclear reprogramming is a powerful tool that enables researchers to direct a skin cell to become another type of tissue or organ. Cooke's team plans to use the activation of innate immunity to regenerate damaged tissues to improve wound healing or recovery after a heart attack.

The research was supported in part by the National Institutes of Health (U01HL100397, HL098049-01A1, and SR00003169/5U01HL099997), the Cancer Prevention and Research Institute of Texas (CPRIT) and the American Heart Association Scientist Development Grant (13SDG17340025).

Sayed N, Ospino F, Himmati F, Lee J, Chanda P, Mocarski ES, Cooke JP.
Retinoic Acid Inducible Gene 1 Protein (RIG1)-like Receptor Pathway is Required for Efficient Nuclear Reprogramming.
Stem Cells. 2017 Mar 9. doi: 10.1002/stem.2607.

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Novartis appoints Bertrand Bodson as Chief Digital…

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, rep...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Amgen and Humana partner for improved health outco…

Two of the nation's leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to i...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

Victoza® reduces the risk of major cardiovascular …

A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high ...

Extended treatment with Brilinta reduces risk of c…

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) fro...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]